

NATUS MEDICAL INC  
Form 8-K  
September 21, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (date of earliest event reported): September 20, 2012**

**Natus Medical Incorporated**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction

of Incorporation)

**000-33001**  
(Commission

File Number)

**77-0154833**  
(I.R.S. Employer

Identification No.)

Edgar Filing: NATUS MEDICAL INC - Form 8-K

**1501 Industrial Road**

**San Carlos, CA 94070**

(Address of principal executive offices)

**650-802-0400**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers**

(b) In connection with an internal restructuring plan, on September 20, 2012 Natus Medical Incorporated (the Company ) notified William L. Mince, Vice President North American Operations, that his position within the Company will be eliminated. It is anticipated that Mr. Mince will continue with the Company during a transition period that extends through December 31, 2012. Pursuant to an employment agreement between the Company and Mr. Mince, upon his departure he will be entitled to certain severance benefits as described under *Employment Agreements and Change of Control Agreements* in the Company s 2012 definitive proxy statement filed with the Commission on April 23, 2012.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NATUS MEDICAL INCORPORATED**  
*(Registrant)*

Dated: September 21, 2012

By: /s/ Steven J. Murphy  
Vice President Finance and Chief Financial Officer